title: David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
authors.forename: I
authors.initials: I
authors.lastname: Miniati
authors.forename: M L
authors.initials: ML
authors.lastname: Conforti
authors.forename: S
authors.initials: S
authors.lastname: Guiducci
authors.forename: M
authors.initials: M
authors.lastname: Matucci Cerinic
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000150:complications*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D003520:Cyclophosphamide; D009173:Mycophenolic Acid